prostate cancer
Updates in Focal Therapy of Prostate Cancer
Thomas J. Polascik, MD, FACS, Professor of Urology at Duke University Medical Center, discusses the effectiveness of focal therapy for prostate cancer as an alternative to radical therapy. He presents...
Real Life MoLEP Case Number 14: Patient In Retention...
This man was recently treated for a stone in a left ureterocoele and as a consequence developed refractory urinary retention. He was under active surveillance for ISUP grade I prostate cancer. We decided...
Updates in Screening: Prostate Cancer Guidelines
Gerald L. Andriole, Jr., MD, a Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine...
Prostate Cancer Genetic Risk Calculator 1.0
Joseph C. Presti, Jr., MD, FACS, Regional Leader of Urologic Oncology Surgery at Kaiser Permanente Northern California, discusses the development of Kaiser Permanente’s new prostate cancer risk calculator...
HIFU: The European Experience
Rafael Sanchez-Salas, MD, attending surgeon at L’Institut Mutualiste Montsouris in Paris, France, and a member of the Focal Therapy Society, discusses high-intensity focused ultrasound treatment (HIFU)...
Con: The Role of Currently Available Biomarkers...
Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, argues that although germline testing is beneficial,...
Con: The Role of Currently Available Biomarkers...
Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, argues that although germline testing is beneficial,...
Pro: The Role of Currently Available Biomarkers...
E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, argues that doctors need to do biomarker testing to know which patients to biopsy, follow closely, and treat with radiation. He discusses...
New Concepts in Cavernous Nerve Localization...
Arthur L. Burnett II, MD, MBA, FACS, Professor of Urology at Johns Hopkins University School of Medicine, discusses therapeutic and investigational strategies for improving erectile function after prostatectomy....
Cesium-131 Prostate Brachytherapy A Single Institutional...
Ronald M. Benoit Jr., MD, Associate Professor, Clinical Vice Chair of Urology, Director of General Urology, and Chief of the Division of Community Urology at the University of Pittsburgh School of Medicine,...
Update on Brachytherapy for Prostate Cancer 2020
Peter J. Rossi, MD, a radiation oncologist with Kaiser Permanente and Valley View Hospital in Glenwood Springs, Colorado, and Steven J. Frank, MD, a professor of radiation oncology at the University of...
Integrating MRI and Molecular Markers to Detect...
Sanoj Punnen, MD, MAS, describes how recent trial based research has supported the synergistic qualities of MRI and biomarkers in the cancer detection process by reducing unnecessary biopsies by approximately...
Technical and Diagnostic Limitations to Partial...
Michael O. Koch, MD, the John Donohue Professor and Chair of Urology at the Indiana University School of Medicine, provides an overview of High-Intensity Focused Ultrasound (HIFU) and Transurethral Ultrasound...
Advanced Prostate Cancer: What's Changing
Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the recent incorporation of advanced prostate cancer (APC) clinics amongst LUGPAs within the United States. He goes on to discuss why...
Review of the Role of MRI Targeted Biopsy vs...
Mukesh Harisinghani, MD, Director of the Clinical Discovery Program Center for Molecular Imaging Research at Massachusetts General Hospital, reviews recent research on the effectiveness of MRI-targeted...